Literature DB >> 16322240

CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics.

Kevin E Sloan1, Jean K Stewart, Allison F Treloar, Russell T Matthews, Daniel G Jay.   

Abstract

We recently identified the immunoglobulin-CAM CD155/PVR (the poliovirus receptor) as a regulator of cancer invasiveness and glioma migration, but the mechanism through which CD155/PVR controls these processes is unknown. Here, we show that expression of CD155/PVR in rat glioma cells that normally lack this protein enhances their dispersal both in vitro and on primary brain tissue. CD155/PVR expression also reduced substrate adhesion, cell spreading, focal adhesion density, and the number of actin stress fibers in a substrate-dependent manner. Furthermore, we found that expression of CD155/PVR increased Src/focal adhesion kinase signaling in a substrate-dependent manner, enhancing the adhesion-induced activation of paxillin and p130Cas in cells adhering to vitronectin. Conversely, depletion of endogenous CD155/PVR from human glioma cells inhibited their migration, increased cell spreading, and down-regulated the same signaling pathway. These findings implicate CD155/PVR as a regulator of adhesion signaling and suggest a pathway through which glioma and other cancer cells may acquire a dispersive phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322240     DOI: 10.1158/0008-5472.CAN-05-1890

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

Review 1.  Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.

Authors:  Christian Goetz; Matthias Gromeier
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-17       Impact factor: 7.638

2.  Anticancer activity of emodin is associated with downregulation of CD155.

Authors:  Liang Fang; Fang Zhao; Stephen Iwanowycz; Junfeng Wang; Sophia Yin; Yuzhen Wang; Daping Fan
Journal:  Int Immunopharmacol       Date:  2019-07-17       Impact factor: 4.932

3.  Recombinant poliovirus for cancer immunotherapy.

Authors:  Millena Prata Jammal; Márcia Antoniazi Michelin; Rosekeila Simões Nomelini; Eddie Fernando Candido Murta
Journal:  Ann Transl Med       Date:  2018-09

4.  The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.

Authors:  Huijun Zhao; Juan Ma; Ting Lei; Wanru Ma; Man Zhang
Journal:  Invest New Drugs       Date:  2018-10-29       Impact factor: 3.850

5.  Polio, still lurking in the shadows.

Authors:  Anthony N van den Pol
Journal:  J Neurosci       Date:  2013-01-16       Impact factor: 6.167

6.  Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.

Authors:  Baobiao Zhuo; Yuan Li; Feng Gu; Zhengwei Li; Qingzeng Sun; Yingchun Shi; Yang Shen; Fengfei Zhang; Rong Wang; Xiaodong Wang
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

7.  The expanding constellation of immune checkpoints: a DNAMic control by CD155.

Authors:  Vincenzo Bronte
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 8.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

9.  Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay.

Authors:  Xiaoyi Yang; Eying Chen; Hengguang Jiang; Karen Muszynski; Raymond D Harris; Steven L Giardina; Matthias Gromeier; Gautam Mitra; Gopalan Soman
Journal:  J Virol Methods       Date:  2008-11-08       Impact factor: 2.014

Review 10.  Oncolytic polio virotherapy of cancer.

Authors:  Michael C Brown; Elena Y Dobrikova; Mikhail I Dobrikov; Ross W Walton; Sarah L Gemberling; Smita K Nair; Annick Desjardins; John H Sampson; Henry S Friedman; Allan H Friedman; Douglas S Tyler; Darell D Bigner; Matthias Gromeier
Journal:  Cancer       Date:  2014-06-17       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.